This is a randomized, placebo-controlled, double-blind study to evaluate the efficacy,
safety, and pharmacodynamics (PD) of multiple doses of REMD-477 in subjects who have Type 1
diabetes and are currently receiving insulin treatment. This study will determine whether
REMD-477 can decrease daily insulin requirements and improve glycemic control after 12 weeks
of treatment in subjects diagnosed with Type 1 diabetes with fasting C-peptide < 0.7 ng/mL at
The study will be conducted at multiple sites in the United States. Approximately 150
subjects with type 1 diabetes on stable doses of insulin will be randomized in a 1:1:1
fashion into one of three treatment groups.
Clinical Study Identifier
REMD Biotherapeutics, Inc.
Last Modified on
21 October 2020
How clear was the trial content above?
Adding a note
Select a piece of text and start making personal notes.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.